免费看性视频xnxxcom丨av在线一区二区三区四区丨亚洲精品网站在线观看你懂的丨久久亚洲a v丨最近的中文字幕丨亚洲在线免费观看丨亚洲不卡av一区二区三区丨成人理论影院丨三级特黄60分钟在线观看丨激情呻吟久久久久久99av丨综合色爱丨国产福利免费丨人妻精品久久无码专区涩涩丨国产亚洲精品第一综合不卡丨亚洲97视频丨天堂网成人丨性欧美xxxx精品xxxxrb丨激情视频免费在线观看丨日本成人不卡丨菲律宾黄色片丨三级毛片国产三级毛片丨国产成人麻豆精品午夜福利在线丨少妇性做爰xxxⅹ性视频丨另类 欧美 日韩 国产 在线丨日韩欧美在线综合网

Many industrial innovative products are coming soon

COVID-19 antibody detection reagent and many other products go out of China and enter the international market

Expanded R&D team and introduced new R&D technology

Realized whole-line cold chain logistics for the first time nationwide

Completed the development and started the clinical test of many industry-leading project, such as irradiator, multiple, HIV, etc.

Be recognized as provincial level innovation and industrialization demonstration enterprise for several times

Established "Guangdong Postdoctoral Innovation Practice Base"

Be approved as a national “Post-Doctoral Research Center”

Established Suzhou R&D center

Moved into the new industrial park with a floor area of 23,000 m2

Cooperated with many international IVD enterprises, such as Unipath, Fujirebro, Siemens, MP, etc.

The market share of AIDS confirmation reagents reached 80%, and the market share of drug concentration detection reached 50%,Many self-developed products occupied over 60% of the market share.Many products became reference methods for disease detection, such as MYCOII and TP.PA.

1989, the first subsidiary of Livzon Pharmaceutical Group Inc.

Obtained pharmaceutical manufacturing license

Many products were successfully developed and marketed, including HBV, HIV, HCV ELISA reagents